Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker

European Journal of Clinical Pharmacology

Volumn 65, Issue 9, 2009, Pages 887-894

  Noehr Jensen, L ^a   Zwisler, S T ^a,b   Larsen, F ^c   Sindrup, S H ^b   Damkier, P ^a,b   Nielsen, F ^a   Brosen, K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Clinical Pharmacology and Pharmacokinetics   (Denmark)

Author keywords

Biomarker; CYP2C19; Escitalopram; Pharmacodynamics; Pharmacokinetics; Pupillometry

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; ESCITALOPRAM; NORESCITALOPRAM; OMEPRAZOLE; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; MYDRIASIS; OBSESSIVE COMPULSIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; PUPIL REFLEX; PUPILLOMETRY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CROSS-OVER STUDIES; DENMARK; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PUPIL; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 69249209932     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0657-0     Document Type: Article

References (25)

1. SR Bareggi E Mundo B Dell'Osso, et al. 2007 The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders Expert Opin Drug Metab Toxicol 3 741 753
2. J Hyttel KP Bogeso J Perregaard, et al. 1992 The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer J Neural Transm Gen Sect 88 157 160
3. C Sánchez 2006 The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram Basic Clin Pharmacol Toxicol 99 91 95
4. J Waugh KL Goa 2003 Escitalopram : a review of its use in the management of major depressive and anxiety disorders CNS Drugs 17 343 362
5. SH Sindrup K Brosen MG Hansen, et al. 1993 Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms Ther Drug Monit 15 11 17
6. M Ingelman-Sundberg SC Sim A Gomez, et al. 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526
7. GC Ibeanu J Blaisdell RJ Ferguson, et al. 1999 A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin J Pharmacol Exp Ther 290 635 640
8. The Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2007) Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: http://www.cypalleles.ki.se/. Accessed 25 Mar 2009
9. K Herrlin N Yasui-Furukori G Tybring, et al. 2003 Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes Br J Clin Pharmacol 56 415 421
10. I Rudberg M Hendset LH Uthus, et al. 2006 Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram) Ther Drug Monit 28 102 105
11. F Fliegert B Kurth K Gohler 2005 The effects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status Eur J Clin Pharmacol 61 257 266
12. JA Schmitt WJ Riedel EF Vuurman, et al. 2002 Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes Psychopharmacology (Berl) 160 381 386
13. U.S. Food and Drug Administration (FDA) (2006) Drug development and drug interactions. FDA, Washington D.C. Available at: http://www.fda.gov/cder/drug/ druginteractions/. Accessed 23 Mar 2009
14. HK Roh ML Dahl G Tybring, et al. 1996 CYP2C19 genotype and phenotype determined by omeprazole in a Korean population Pharmacogenetics 6 547 551
15. M Chang ML Dahl G Tybring, et al. 1995 Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics 5 358 363
16. JA Goldstein J Blaisdell 1996 Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism Methods Enzymol 272 210 218
17. RJ Ferguson SM De Morais S Benhamou, et al. 1998 A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin J Pharmacol Exp Ther 284 356 361
18. B Sogaard H Mengel N Rao, et al. 2005 The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects J Clin Pharmacol 45 1400 1406
19. I Rudberg B Mohebi M Hermann, et al. 2008 Impact of the ultrarapid CYP2C19 17 allele on serum concentration of escitalopram in psychiatric patients Clin Pharmacol Ther 83 322 327
20. B Saletu J Grunberger L Linzmayer 1986 On central effects of serotonin reuptake inhibitors-quantitative EEG and psychometric studies with sertraline and zimelidine J Neural Transm 67 241 266
21. J Mcguirk T Silverstone 1990 The effect of the 5-HT reuptake inhibitor fluoxetine on food-intake and body-weight in healthy male-subjects Int J Obes 14 361 372
22. B Saletu J Grunberger L Linzmayer 1986 On central effects of serotonin reuptake inhibitors-quantitative EEG and psychometric studies with sertraline and zimelidine J Neural Transm 67 241 266
23. P Blier M El Mansari 2007 The importance of serotonin and noradrenaline in anxiety Int J Psychiat Clin 11 16 23
24. G Chidlow PS Hiscott NN Osborne 2004 Expression of serotonin receptor mRNAs in human ciliary body: a polymerase chain reaction study Graefes Arch Clin Exp Ophthalmol 242 259 264
25. NA Sharif M Senchyna 2006 Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR Mol Vis 12 1040 1047